Ranking Profile - Eloxx Pharmaceuticals Inc

Introduction

Eloxx Pharmaceuticals Inc (Eloxx), formerly Sevion Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops novel RNA-modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company's lead product candidate, ELX-02, is in Phase II clinical trials for the treatment of cystic fibrosis. Its preclinical candidates include novel ERSG drug candidates for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and Usher syndrome. The company has a subsidiary in Israel. Eloxx is headquartered in Watertown, Massachusetts, the US.